Orthopediatrics Corp (NASDAQ:KIDS) was the recipient of a significant increase in short interest during the month of June. As of June 15th, there was short interest totalling 759,100 shares, an increase of 8.3% from the May 15th total of 701,000 shares. Currently, 9.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 73,900 shares, the short-interest ratio is presently 10.3 days.
KIDS has been the topic of several recent analyst reports. Needham & Company LLC set a $69.00 price objective on shares of Genomic Health and gave the company a “buy” rating in a research report on Wednesday, June 19th. BidaskClub cut shares of Ames National from a “hold” rating to a “sell” rating in a research report on Wednesday. Zacks Investment Research cut shares of Hess Midstream Partners from a “hold” rating to a “sell” rating in a research report on Tuesday, May 14th. Finally, BTIG Research dropped their price objective on shares of Verastem to $8.00 and set a “buy” rating for the company in a research note on Friday, May 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $46.75.
NASDAQ KIDS traded down $0.93 on Friday, hitting $34.83. 57,833 shares of the stock were exchanged, compared to its average volume of 106,890. The company has a quick ratio of 6.01, a current ratio of 8.60 and a debt-to-equity ratio of 0.26. The business has a fifty day moving average price of $38.96. The stock has a market capitalization of $511.23 million, a price-to-earnings ratio of -36.28 and a beta of 0.14. Orthopediatrics has a 52-week low of $25.11 and a 52-week high of $47.82.
Institutional investors have recently made changes to their positions in the business. Pura Vida Investments LLC raised its holdings in Orthopediatrics by 15.9% in the fourth quarter. Pura Vida Investments LLC now owns 116,831 shares of the company’s stock worth $4,075,000 after purchasing an additional 15,997 shares in the last quarter. Rhumbline Advisers raised its holdings in Orthopediatrics by 55.5% in the fourth quarter. Rhumbline Advisers now owns 8,770 shares of the company’s stock worth $306,000 after purchasing an additional 3,129 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Orthopediatrics by 20.5% during the third quarter. JPMorgan Chase & Co. now owns 70,225 shares of the company’s stock valued at $2,573,000 after acquiring an additional 11,931 shares in the last quarter. Royce & Associates LP increased its holdings in shares of Orthopediatrics by 7.2% during the fourth quarter. Royce & Associates LP now owns 193,500 shares of the company’s stock valued at $6,749,000 after acquiring an additional 13,000 shares in the last quarter. Finally, Bank of Montreal Can increased its holdings in shares of Orthopediatrics by 4,156.3% during the fourth quarter. Bank of Montreal Can now owns 2,043 shares of the company’s stock valued at $71,000 after acquiring an additional 1,995 shares in the last quarter. Institutional investors and hedge funds own 48.63% of the company’s stock.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.
Further Reading: What is a recession?
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.